Key Takeaways: Head-to-Head Comparison of 18F-Fluciclovine and 68Ga-PSMA-11 in Prostate Cancer
January 24th 2022Reactions to key findings from an article by Birgit Pernthaler, et al, that compared the use of 18F-fluciclovine with 68Ga-PSMA-11 imaging modalities to detect biochemical relapse in prostate cancer.
Presentation: Head-to-Head Comparison of 18F-Fluciclovine and 68Ga-PSMA-11 in Prostate Cancer
January 20th 2022Drs Steven Finkelstein and Louis J. Mazzarelli highlight data revealed in the article “A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT,” by Birgit Pernthaler, et al.
Background: 18F-Fluciclovine and 68Ga-PSMA-11 Imaging in Prostate Cancer
December 23rd 2021Drs Steven Finkelstein and Louis J. Mazzarelli comment on limitations associated with conventional imaging modalities in prostate cancer and highlight the roles of newer tests such as 18F-fluciclovine and 68Ga-PSMA-11.
Inside the RadPartners-MEDNAX Fusion: What's To Come
December 17th 2020Diagnostic Imaging spoke with Radiology Partners Chairman and CEO Rich Whitney, Associate CMO Nina Kottler, M.D., and MEDNAX Radiology Solutions CMO Ricardo Cury, M.D., about this newly finalized partnership, what it means for the companies, and how it could impact the industry.